Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across ...

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its ...

Bristol-Myers Squibb Company (($BMY)) has held its Q2 earnings call. Read on for the main highlights of the call.

Emma Charles shares her vision for healthcare, how AI is reshaping pharma and why access to innovation must be faster and ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were ...